share_log

康哲藥業：截至二零二四年六月三十日止六個月之中期業績公告及董事調任

CMS: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024 AND RE-DESIGNATION OF DIRECTOR

HKEX ·  Aug 15 07:08

Summary by Moomoo AI

康哲藥業控股有限公司（CMS）公佈截至2024年6月30日止六個月的未經審計中期業績，營業額同比下降21.7%，至人民幣3,611.1百萬元。毛利同比下降25.2%，至人民幣2,696.5百萬元。期間溢利同比下降52.8%，至人民幣903.4百萬元。每股基本盈利同比下降52.3%，至人民幣0.3734元。公司宣派中期股息每股人民幣0.1507元，同比下降51.9%。公司表示，國家帶量採購對業績產生負面影響，但標誌著國採對公司的負面影響已基本消化。公司將持續推動創新產品的佈局、臨床開發進程，推出更多創新產品上市銷售，驅動集團取得持續的高質量發展。此外，陳洪兵先生辭任首席營運官及副總裁，由執行董事調任為非執行董事，並獲聘為資深顧問。
康哲藥業控股有限公司（CMS）公佈截至2024年6月30日止六個月的未經審計中期業績，營業額同比下降21.7%，至人民幣3,611.1百萬元。毛利同比下降25.2%，至人民幣2,696.5百萬元。期間溢利同比下降52.8%，至人民幣903.4百萬元。每股基本盈利同比下降52.3%，至人民幣0.3734元。公司宣派中期股息每股人民幣0.1507元，同比下降51.9%。公司表示，國家帶量採購對業績產生負面影響，但標誌著國採對公司的負面影響已基本消化。公司將持續推動創新產品的佈局、臨床開發進程，推出更多創新產品上市銷售，驅動集團取得持續的高質量發展。此外，陳洪兵先生辭任首席營運官及副總裁，由執行董事調任為非執行董事，並獲聘為資深顧問。
CMS Holdings Co., Ltd. (CMS) has announced its unaudited interim results for the six months ended June 30, 2024. The operating income decreased by 21.7% year-on-year to RMB 361.11 million, gross profit decreased by 25.2% year-on-year to RMB 269.65 million, net profit decreased by 52.8% year-on-year to RMB 90.34 million, and basic earnings per share decreased by 52.3% year-on-year to RMB 0.3734. The company declared a mid-year dividend of RMB 0.1507 per share, a year-on-year decrease of 51.9%. The company stated that the national volume-based procurement policy has had a negative impact on its performance, but it marks a basic digestion of the negative impact to the company by national procurement. The company will continue to promote the layout of innovative products, clinical development processes, launch more innovative products for sale, and drive the group to achieve sustained high-quality development. In addition, Mr. Chen Hongbing resigned as Chief Operating Officer and Vice President, was transferred by Executive Director to Non-Executive Director, and was appointed as a senior consultant.
CMS Holdings Co., Ltd. (CMS) has announced its unaudited interim results for the six months ended June 30, 2024. The operating income decreased by 21.7% year-on-year to RMB 361.11 million, gross profit decreased by 25.2% year-on-year to RMB 269.65 million, net profit decreased by 52.8% year-on-year to RMB 90.34 million, and basic earnings per share decreased by 52.3% year-on-year to RMB 0.3734. The company declared a mid-year dividend of RMB 0.1507 per share, a year-on-year decrease of 51.9%. The company stated that the national volume-based procurement policy has had a negative impact on its performance, but it marks a basic digestion of the negative impact to the company by national procurement. The company will continue to promote the layout of innovative products, clinical development processes, launch more innovative products for sale, and drive the group to achieve sustained high-quality development. In addition, Mr. Chen Hongbing resigned as Chief Operating Officer and Vice President, was transferred by Executive Director to Non-Executive Director, and was appointed as a senior consultant.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated